Besides the important role of murine monoclonal antibodies (MAbs) in basic research and in vitro diagnosis, they became important tools for in vivo diagnosis of tumours (Murray & Unger, 1988) , inflammatory processes (Joseph et al., 1988) and thrombosis (Haber et al., 1990) . Furthermore it was clinically proven that murine MAbs inhibit transplantation rejection (Goldstein, 1987; Kurrle et al., 1988) and interfere with gram negative sepsis (Greenman et al., 1991) . No clearcut clinical benefit, however, was shown so far in the therapy of solid tumours either with cytotoxic murine MAbs or MAb-drug conjugates (Dykes et al., 1987) . This is mainly due to the unfavourable tumour tissue penetration characteristics and whole body distribution of macromolecules such as MAbs (Thomas et al., 1989) , causing severe damages in normal tissue as well. This can be optimised using the recently described two phase immunotherapy approaches (Bosslet et al., 1991) based on bispecific MAbs. BsMAbs offer a unique possibility for the two phase immunotherapy consisting of a long-term binding phase of the nontoxic bsMAbs to tumour cells and, after the elimination of unbound bsMAb, a short-term binding phase of an effector system. In our approach, we intend to use a bsMAb with binding specificity for a tumour associated antigen (carcinoembryonic antigen, CEA) on one arm and to a radiolabelled chelate (DTPA-9Y) on the other arm for a two phase radioimmunotherapy.
BsMAbs have been generated either by chemical linking of the reduced monovalent parental Fab' fragments to form a bispecific F(ab')2 fragment (Brennan et al., 1985; Bagshawe et al., 1989) , using the quadroma technique (Milstein & Cuello, 1983) , by double transfection of murine Ig genes (Lenz & Weidle, 1990) or by double transfection of chimeric DNA constructs (Songsivilai et al., 1989) . A murine bsMAb with the above mentioned specificities, generated by double fusion has already been described (Bosslet et al., 1991) .
Unfortunately repetitive high dose injection of murine monoclonal antibodies in immunotherapy often induced the development of human anti-mouse-Ig antibodies (HAMA) in patients, which prevent prolonged treatment (Miller et al., 1983; Kroonenburgh, van & Pauwels, 1988) . Consequently, the target was to produce a MAb capable of escaping surveillance by the human immune system while retaining the specificity of the murine parental antibody. In a first approach, the V-regions of murine antibodies were recombined with human constant region genes to form chimeric MAbs (Boulianne et al., 1984; Morrison et al., 1984) . Lately, the antigen binding loops or complementarity-determining regions (CDRs) of the mouse VH and VL domains have successfully been transplanted to the VH and VL domains of human myeloma proteins without major impairment of the antigen binding capacity (Jones et al., 1986; Riechmann et al., 1988) .
One of these humanised MAb has already been applied in patients (Hale et al., 1988) , without inducing a detectable immune response against the molecule.
In this report, we describe the generation of a bifunctional
MAb consisting of one humanised anti-CEA arm and a chimerised anti-DTPA-Y arm by double transfection of the corresponding genes into BHK cells, its purification using immunoaffinity chromatography and its characterisation.
Materials and methods
Production of CEA-and DTPA-specific murine MAbs
The generation and screening of murine MAbs directed against CEA (BW 431) and DTPA-Y (BW 2050), respectively, was described previously (Graham & van der Eb, 1973) . Two plasmids carrying resistance genes for methotrexate (Subramani et al., 1981) and G418 (Hudziak et al., 1982) as selection markers were cotransfected. A BHK cell line which had been selected for the production of humanised anti-CEA MAb and the binding of anti-idiotypic antibody (Gussow & Seemann, 1991) was transfected a second time with the chimeric genes coding for the heavy and light chains of MAb BW 2050. The resistance gene for hygromycin (Gritz & Davies, 1983) was cotransfected for the selection of double transfectomas.
Cells were seeded out in a modified Dulbecco's medium containing human insulin and all three resistance markers (Mtx, G418, hygromycin). Clones grew out 2-3 weeks after transfection.
Screening of the double transfectomas Transfectoma supernatants were screened for the presence of bispecific MAb using an ELISA system in which HSAbenzyl-DTPA (50 ng ml-') was attached to the solid phase of round bottom polystyrol plates (Nunc). Bound MAb was detected using a murine anti-idiotypic antibody (IgG2b) (Bosslet et al., 1990) , selective for the murine as well as the humanised anti-CEA MAb BW 431, and an alkaline phosphatase labelled goat anti-mouse-IgG2b antibody (Southern, Birmingham, USA) combined with the alcohol dehydrogenase-diaphorase amplification system (Stanley et al., 1985 ; system III). Optical density was measured at 493 nm using a Titertek multiscan type 3100 (Flow Laboratories). Double affinity chromatography Protein A-sepharose-purified anti-idiotypic MAb specific for BW 431 was coupled to cyanogen bromide-activated Sepharose at a concentration of 6.5 mg MAb ml -gel according to van Eijk and van Noort (1976) . Supernatant of double transfectoma was loaded on the column. After extensive washing with phosphate-buffered saline (PBS), pH 7.2, specifically bound antibodies were eluted using PBS, pH 4.0. On a second column, antigen (HSA-benzyl-DTPA) was covalently coupled to CNbr-activated Sepharose at a concentration of 8 mg ml-' gel. The MAb eluted from the anti-id column was loaded on the HSA-benzyl-DTPA column. After washing with PBS, pH 7.2, the bispecific MAbs were eluted with double distilled water containing 25% glycerine, and adjusted to pH 2.3
The enrichment of bispecific MAb was monitored using three ELISA systems which allowed the determination of the functional anti DTPA arm (system 1), a functional anti CEA arm (system 2) or both arms (system 3). Technical details of the systems are identical to those described in screening of the double transfectomas.
System I uses HSA benzyl-DTPA on the solid phase (coating concentration: 50 ng ml-') combined with AP-labelled anti human K antibody (50 ng ml-', Southern Biotechnology h.c., Birmingham).
In system II CEA at a concentration of 50ngml-' was attached to the solid phase instead of HSA-benzyl-DTPA.
System III was described in chapter 'Screening of the double transfectomas'.
Characterisation of bsMAbs in SDS-Polyacrylamide-gel electrophoresis Samples were analysed either unreduced or reduced with 50 mM DTT by SDS-PAGE (Laemmli, 1970) , carried out in a Mini Protean II Electrophoresis Cell (Bio-Rad, Richmond, Ca., USA) using a 10% stacking gel combined with a separation gel of 4-15% (Bio-Rad). The gels were stained using Coomassie Blue according to the manufacturers' procedure (PhastGel'm Blue R, Pharmacia LKB, Sweden).
Quantitative binding assay in antigen excess Four hundred ng ml-' of purified humanised bispecific MAb were incubated with increasing amounts of antigen. Antigen consisted of CEA-expressing HT 29 colon carcinoma xenografts which were fixed using 5% formaldehyde for 5 days and squeezed after cutting in 1-3 mm3 cubes through a stainless steel sieve. This methodology generates single dead round cell bodies, defined as ACM (antigen containing material). After a 4 h incubation at room temperature the antigen was spun down and the amount of unbound MAb in the supernatant was determined using a quantitative ELISA specific for human IgG (anti-human-IgG attached to the solid-phase). The fraction of unbound MAb detectable in the supernatant in antigen excess represents the inactive fraction of the purified bsMAb preparation. Immunoreactivity (I.R.) was determined according to the formula
The point of determination was the highest amount of antigen at which there was no unspecific binding of the chimeric negative control MAb BW 554, selective for ganglioside GD2.
Evaluation of the anti DTPA-arm One fg ml-' of HSA-Benzyl-DTPA-Y was used to coat microtitre plates. Constant amounts (1I00 tg ml-') of bsMAb purified by affinity chromatography were mixed with increasing amounts of DTPA-Y starting with 0.1 ng ml-' up to 
Purification of humanised bsMAb
Ten litres supernatant of clone A 10 were concentrated and purified using two consecutive affinity chromatography columns, first an anti-id column and second an antigen column. The effect of the individual purification steps was investigated using three different ELISAs, detecting the anti-DTPA-Y arm (system I), the anti CEA arm (system II), and both arms (system III). BsMAb could be separated from the non bispecific molecules which appear by false recombinations of heavy and light chains. The data, presented in Table I , show a) the increase of activity in system II (specific for CEA) after anti-idiotypic affinity chromatography, and b) the increase of activity in system I (specific for DTPA-Y) after antigen affinity chromatography in the eluates in question. Coincidental there is a decrease of activity in the flow throughs of both columns.
Out of 32 mg of IgG which could be detected via ELISA in 10 1 of supernatant of A 10, 3.1 mg were left over after double immunoaffinity purification. The yield of 10% was in the range suggested according to the theoretical considerations from Milstein and Cuello (1983) . (BW 554) in an ELISA after incubation of constant amounts of antibody with increasing amounts of particle attached CEA as described in Materials and methods (Figure 3) .
Immunoreactivity was calculated, based on the IgG concentrations determined by ELISA, according to the formula given in Materials and methods. Calculations indicated that 95% of the preparation of bispecific MAb consisted of immunoreactive material, compared to 96% as determined for the monospecific humanised MAb BW 431 (see Table II) . Evaluation of the anti DTPA-Y arm The binding potential of the bsMAb to HSA-benzyl DTPA-Y was determined in a competitive ELISA system as described in Materials and methods. Increasing amounts of DTPA-Y as a competitor resulted in a decrease of the binding signal in the ELISA down to background level (data not shown). These data indicate that free DTPA-Y is able to block the binding of the bsMAb to solid phase attached HSA-benzyl DTPA-Y, arguing for the functional integrity of the anti DTPA-Y arm.
Discussion
We have established a humanised bispecific monoclonal antibody consisting of a humanised anti-CEA arm and a chimerised anti-DTPA-Y arm. The bispecific molecule is of IgG3 isotype and has a shortened hinge region: instead of normally four, the AIgG3 gene has only one exon, reducing the possible disulfide bonds from 11 to 3. We were able to generate this bsMAb by two successive, calcium-phosphate mediated transfections of an eucaryotic BHK cell line. Out of several hundred clones, only three stably produced bsMAbs detectable in a double determinant ELISA. For purification purposes we had to load the culture supernatant on two consecutive immunoaffinity chromatography columns, first presenting an anti-idiotypic antibody, selective for the CEA arm, and second the antigen for the anti-DTPA arm. Purification was controlled by three ELISA systems (Table I) , which proved that there was an increase of activity in the eluates and a coincidental decrease of activity in the flow through of the two columns. We were able to quantitatively separate 10% of bispecific monovalent antibodies from falsely recombined molecules, a yield which correlates with the theoretical considerations of Milstein and Cuello (1983) . Ninety-five per cent of the bispecific molecules were immunoreactive as revealed by a quantitative binding assay in antigen excess (Table II) . Compared to other methods (Doussal et al., 1989; Lenz & Weidle, 1990) this purification method leads to exceptionally high yields. Disadvantageous was the yield of the BHK cells secreting the immunoglobulins: from a cell line which had produced 4-8 g ml-' in the beginning, we only harvested about 30 mg immunoglobulin from 101 supernatant instead of 40-80 mg expected. It has to be accepted that to some extent the cells lost the specificity of antibody production. In another case of antibody production in BHK cells in our laboratory it was revealed that the cells produced much more light chains than heavy chains (Bosslet, unpublished data) , a fact which leads to reduced yields of intact molecules. Combined with the fact that two affinity chromatography columns are necessary for purification, these conditions are unfavourable for larger production scales.
Comparison of the humanised bsMAb and the humanised monospecific anti-CEA antibody in SDS-PAGE proved that both molecules resemble each other to a large extent. The most obvious differences appear in the behaviour of the light chains of both antibodies which point to the presence of two different K-chains in the bsMAb (Figure 2, lanes 5 and 6) . This may be due to the fact that one of the light chains still has a whole murine variable region. The integrity of the bispecific MAb was further proven by our immunoreactivity studies indicating that >95% of the bispecific humanised MAb were functionally active. This immunoreactivity is only marginally inferior to the value generated using the humanised monospecific MAb (>96%-.
The anti DTPA-Y could only be evaluated qualitatively. Data from the competitive ELISA system in which the binding of the bsMAb to solid phase attached HSA-benzyl DTPA-Y was completely blocked by a > 100 fold excess of free DTPA-Y, argue for the functional integrity and specificity of those bsMAb molecules which bound to the solid phase attached HSA-benzyl DTPA-Y. This type of analysis is less quantitative than the immunoreactivity assay performed for the anti CEA arm, but is nevertheless suited to support the usefulness of the hu bsMAb.
The bispecific MAb generated is intended to be employed in two phase radioimmunotherapy, having dual specificity for carcino-embryonic antigen (CEA) and a radiolabelled chelate (DTPA-90Y). Concerning the specific tumour localisation, Bosslet et al. (1991) showed that it is possible to obtain a significant tissue penetration of solid human carcinoma xenografts after long time application of the murine anti-CEA MAb BW 431. Since the two phase therapy concept is built up on repetitive long-term and high dose injections of bispecific antibodies, immunisation of patients is most probable. The humanised bsMAb is hoped to overcome the problem of immunogenicity currently seen with murine and chimeric antibodies used in human therapy (Briiggemann et al., 1989) .
Considering the yields and the cumbersome purification procedure, attempts have been made to improve the yield of bispecific monovalent MAb using recombinant DNA technology, e.g. the construction of an Ig heavy chain, consisting of VH of MAB 1 and a CHl domain, which is linked by a polypeptide spacer to the other heavy chain, consisting of VH of MAb 2 and a CH3 domain, to form a 'tandem heavy chain'. The association of such a 'tandem heavy chain' with the two corresponding light chains (VK of MAb 1 and a Cx domain or VK of MAb 2 and a CH3 domain) should lead predominantly to the formation of the desired bispecific molecule.
